Erasca, Inc. (ERAS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.12: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality.
Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, with two Phase 1 clinical programs: ERAS-0015 (pan-RAS molecular glue, AURORAS-1 trial) and ERAS-4001 (pan-KRAS inhibitor, BOREALIS-1 trial). The company has no approved products or... Read more
Sell if holding. Engine safety override at $11.12: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Erasca, Inc.
Latest news
- Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26 — benzinga May 12, 2026 positive
- Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate — benzinga May 11, 2026 negative
- Erasca Announces Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate ERAS-0015 In Combination With — benzinga May 11, 2026 positive
- 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Apr 28, 2026 neutral
- Crude Oil Gains Over 3%; General Motors Earnings Top Views — benzinga Apr 28, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.12: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $10.35. Score 5.1/10, moderate confidence.
Take-profit target: $17.66 (+58.7% upside). Prior stop was $10.35. Stop-loss: $10.35.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 6.8), Material insider selling (19 sells, 0.02% of cap).
Erasca, Inc. trades at a P/E of N/A (forward -18.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ERAS with a consensus score of 4.1/5. Average price target: $20.
What does Erasca, Inc. do?Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, with two Phase 1...
Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, with two Phase 1 clinical programs: ERAS-0015 (pan-RAS molecular glue, AURORAS-1 trial) and ERAS-4001 (pan-KRAS inhibitor, BOREALIS-1 trial). The company has no approved products or revenue; it funds operations from equity, with cash extended into 2H 2028 following a $242.7M public offering in January 2026.